Raltegravir 1200  mg once daily as maintenance therapy in virologically suppressed HIV-1 infected adults: QDISS open-label trial

CONCLUSION: RAL 1200 mg qd as part of a maintenance triple therapy showed a high efficacy in virologically suppressed HIV-1 infected subjects, with good safety profile and improved lipid profile and patient reported outcomes.TRIAL REGISTRATION: Clinical trials.gov NCT03195452 and EudraCT 2016-003702-13.PMID:35033092 | PMC:PMC8760827 | DOI:10.1186/s12981-022-00428-5

Source: AIDS Research and Therapy - January 16, 2022 Category: Infectious Diseases Authors: Nolwenn Hall Clotilde Allavena Christine Katlama Alexandra Jobert Jean-Michel Molina Eric Cua Firouz é Bani-Sadr Laurent Hocqueloux Claudine Duvivier Dominique Merrien Hitoto Hikombo Elisabeth Andr é-Garnier Aur élie Gaultier Fran çois Raffi QDISS Stu Source Type: research